| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,760,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inozyme Pharma is a rare disease biopharmaceutical company developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Co.'s product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ectonucleotide pyrophosphatase/phosphodiesterase 1 and adenosine triphosphate-Binding Cassette in the C6 Deficiencies. This pathway is central to the regulation of calcium deposition throughout the body and is further associated with neointimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,114,598 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10,849,994 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
8,819 |
8,819 |
8,819 |
16,342 |
| Total Sell Value |
$7,849 |
$7,849 |
$7,849 |
$60,059 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
2 |
| End Date |
2025-02-09 |
2024-11-08 |
2024-05-10 |
2023-05-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Treco Douglas A |
CEO & Chairman |
• • – |
2025-04-02 |
4 |
S |
$0.89 |
$7,849 |
D/D |
(8,819) |
41,046 |
|
- |
|
| Treco Douglas A |
CEO & Chairman |
• • – |
2025-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
49,865 |
|
- |
|
| Winton Matthew |
COO |
• – – |
2025-03-31 |
4 |
A |
$0.77 |
$1,917 |
D/D |
2,490 |
7,388 |
|
- |
|
| Subramanian Sanjay |
SVP, CFO & Head of BD |
• – – |
2025-03-31 |
4 |
A |
$0.77 |
$1,917 |
D/D |
2,490 |
32,888 |
|
- |
|
| Winton Matthew |
COO |
• – – |
2024-09-30 |
4 |
A |
$4.45 |
$7,610 |
D/D |
1,710 |
4,898 |
|
- |
|
| Treco Douglas A |
CEO |
• • – |
2024-09-30 |
4 |
A |
$4.45 |
$7,610 |
D/D |
1,710 |
22,375 |
|
- |
|
| Treco Douglas A |
CEO |
• • – |
2024-04-02 |
4 |
S |
$6.94 |
$52,210 |
D/D |
(7,523) |
20,665 |
|
- |
|
| Treco Douglas A |
CEO |
• • – |
2024-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
28,188 |
|
- |
|
| Winton Matthew |
COO |
• – – |
2024-03-28 |
4 |
A |
$3.33 |
$10,616 |
D/D |
3,188 |
3,188 |
|
- |
|
| Subramanian Sanjay |
SVP, CFO |
• – – |
2023-09-29 |
4 |
A |
$3.57 |
$8,279 |
D/D |
2,319 |
30,398 |
|
- |
|
| Pivotal Bioventure Partners Fund I U.g.p., Ltd |
|
– • – |
2023-08-01 |
4 |
B |
$4.80 |
$3,999,998 |
I/I |
833,333 |
1,571,741 |
0.01 |
- |
|
| Hopfner Robert Lorne |
|
– • – |
2023-08-01 |
4 |
B |
$4.80 |
$3,999,998 |
I/I |
833,333 |
1,571,741 |
0.01 |
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2023-05-12 |
4 |
B |
$6.25 |
$1,429,388 |
I/I |
228,702 |
3,661,518 |
2.1 |
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2023-05-11 |
4 |
B |
$6.48 |
$1,420,610 |
I/I |
219,230 |
3,432,816 |
2.1 |
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2023-03-29 |
4 |
B |
$4.54 |
$1,563,724 |
I/I |
344,592 |
3,213,586 |
2.1 |
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2023-03-28 |
4 |
B |
$4.16 |
$652,335 |
I/I |
156,766 |
2,868,994 |
2.1 |
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2023-03-27 |
4 |
B |
$3.70 |
$188,729 |
I/I |
51,074 |
2,712,228 |
2.1 |
- |
|
| Bjarke Henric Bjorn |
SVP, COO |
• – – |
2022-12-15 |
4 |
B |
$1.39 |
$29,885 |
D/D |
21,500 |
105,441 |
2.74 |
- |
|
| Bjarke Henric Bjorn |
SVP, COO |
• – – |
2022-09-30 |
4 |
A |
$2.28 |
$7,558 |
D/D |
3,315 |
83,941 |
|
- |
|
| Bolte Axel |
Chief Executive Officer |
• • – |
2022-09-30 |
4 |
A |
$2.28 |
$7,558 |
D/D |
3,315 |
261,890 |
|
- |
|
| Enright Patrick G |
10% Owner |
– – • |
2022-04-19 |
4 |
B |
$3.69 |
$4,999,950 |
I/I |
1,355,000 |
4,174,379 |
1.5 |
- |
|
| Bolte Axel |
Chief Executive Officer |
• • – |
2022-04-19 |
4 |
B |
$3.69 |
$249,998 |
D/D |
67,750 |
258,575 |
2.81 |
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2022-04-19 |
4 |
B |
$3.69 |
$3,948,300 |
I/I |
1,070,000 |
2,661,154 |
2.1 |
- |
|
| Subramanian Sanjay |
SVP, CFO |
• – – |
2022-04-19 |
4 |
B |
$3.69 |
$99,999 |
D/D |
27,100 |
27,100 |
2.74 |
- |
|
| Bjarke Henric Bjorn |
SVP, COO |
• – – |
2022-04-19 |
4 |
B |
$3.69 |
$99,999 |
D/D |
27,100 |
80,626 |
2.74 |
- |
|
67 Records found
|
|
Page 1 of 3 |
|
|
